-
1
-
-
79953326383
-
Malignant pleural mesothelioma: the standard of care and challenges for future management
-
May
-
van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol 2011 May;78(2):92-111.
-
(2011)
Crit Rev Oncol Hematol
, vol.78
, Issue.2
, pp. 92-111
-
-
van Meerbeeck, J.P.1
Scherpereel, A.2
Surmont, V.F.3
Baas, P.4
-
2
-
-
34547656272
-
Malignant mesothelioma: global incidence and relationship with asbestos
-
Jun
-
Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007 Jun;45(3):379-87.
-
(2007)
Ind Health
, vol.45
, Issue.3
, pp. 379-387
-
-
Bianchi, C.1
Bianchi, T.2
-
3
-
-
0034577215
-
Malignant mesothelioma in central and Eastern Europe
-
Bianchi C, Brollo A, Ramani L, Bianchi T. Malignant mesothelioma in central and Eastern Europe. Acta Med Croat 2000;54(4-5):161-4.
-
(2000)
Acta Med Croat
, vol.54
, Issue.4-5
, pp. 161-164
-
-
Bianchi, C.1
Brollo, A.2
Ramani, L.3
Bianchi, T.4
-
4
-
-
26444458845
-
Advances in malignant mesothelioma
-
Oct 13
-
Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005 Oct 13;353(15):1591-603.
-
(2005)
N Engl J Med
, vol.353
, Issue.15
, pp. 1591-1603
-
-
Robinson, B.W.1
Lake, R.A.2
-
5
-
-
79958053931
-
Novel targeted therapies and vaccination strategies for mesothelioma
-
Jun
-
Bagia M, Nowak AK. Novel targeted therapies and vaccination strategies for mesothelioma. Curr Treat Options Oncol 2011 Jun;12(2):149-62.
-
(2011)
Curr Treat Options Oncol
, vol.12
, Issue.2
, pp. 149-162
-
-
Bagia, M.1
Nowak, A.K.2
-
6
-
-
84883050318
-
Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies
-
Sep
-
Robert C, Soria JC, Eggermont AM. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer 2013 Sep;49(14):2968-71.
-
(2013)
Eur J Cancer
, vol.49
, Issue.14
, pp. 2968-2971
-
-
Robert, C.1
Soria, J.C.2
Eggermont, A.M.3
-
7
-
-
84899742483
-
Immunotherapy for malignant pleural mesothelioma. Current status and future prospects
-
May
-
Wong RM, Ianculescu I, Sharma S, Gage DL, Olevsky OM, Kotova S, et al. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects. Am J Respir Cell Mol Biol 2014 May;50(5):870-5.
-
(2014)
Am J Respir Cell Mol Biol
, vol.50
, Issue.5
, pp. 870-875
-
-
Wong, R.M.1
Ianculescu, I.2
Sharma, S.3
Gage, D.L.4
Olevsky, O.M.5
Kotova, S.6
-
8
-
-
84879759020
-
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
-
Jul 11
-
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013 Jul 11;369(2):134-44.
-
(2013)
N Engl J Med
, vol.369
, Issue.2
, pp. 134-144
-
-
Hamid, O.1
Robert, C.2
Daud, A.3
Hodi, F.S.4
Hwu, W.J.5
Kefford, R.6
-
9
-
-
84872514622
-
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody
-
Jan 15
-
Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013 Jan 15;19(2):462-8.
-
(2013)
Clin Cancer Res
, vol.19
, Issue.2
, pp. 462-468
-
-
Lipson, E.J.1
Sharfman, W.H.2
Drake, C.G.3
Wollner, I.4
Taube, J.M.5
Anders, R.A.6
-
10
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Jun 28
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 Jun 28;366(26):2443-54.
-
(2012)
N Engl J Med
, vol.366
, Issue.26
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
11
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Jun 28
-
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012 Jun 28;366(26):2455-65.
-
(2012)
N Engl J Med
, vol.366
, Issue.26
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
-
12
-
-
84884703526
-
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
-
Oct
-
Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013 Oct;14(11):1104-11.
-
(2013)
Lancet Oncol
, vol.14
, Issue.11
, pp. 1104-1111
-
-
Calabro, L.1
Morra, A.2
Fonsatti, E.3
Cutaia, O.4
Amato, G.5
Giannarelli, D.6
-
13
-
-
0033517152
-
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
-
Aug 2
-
van EA, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999 Aug 2;190 (3):355-66.
-
(1999)
J Exp Med
, vol.190
, Issue.3
, pp. 355-366
-
-
van, E.A.1
Hurwitz, A.A.2
Allison, J.P.3
-
14
-
-
84906935302
-
Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
-
Sep
-
Pico de CY, Masucci G, Hansson J, Kiessling R. Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy. Cancer Immunol Immunother 2014 Sep;63(9):977-83.
-
(2014)
Cancer Immunol Immunother
, vol.63
, Issue.9
, pp. 977-983
-
-
Pico de, C.Y.1
Masucci, G.2
Hansson, J.3
Kiessling, R.4
-
15
-
-
0034669916
-
Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor
-
Nov 15
-
Pioli C, Gatta L, Ubaldi V, Doria G. Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor. J Immunol 2000 Nov 15;165 (10):5530-6.
-
(2000)
J Immunol
, vol.165
, Issue.10
, pp. 5530-5536
-
-
Pioli, C.1
Gatta, L.2
Ubaldi, V.3
Doria, G.4
-
16
-
-
0037220271
-
CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells
-
Jan 1
-
Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003 Jan 1;101(1):202-9.
-
(2003)
Blood
, vol.101
, Issue.1
, pp. 202-209
-
-
Pistillo, M.P.1
Tazzari, P.L.2
Palmisano, G.L.3
Pierri, I.4
Bolognesi, A.5
Ferlito, F.6
-
17
-
-
0036122958
-
Expression of CTLA-4 by human monocytes
-
Jan
-
Wang XB, Giscombe R, Yan Z, Heiden T, Xu D, Lefvert AK. Expression of CTLA-4 by human monocytes. Scand J Immunol 2002 Jan;55(1):53-60.
-
(2002)
Scand J Immunol
, vol.55
, Issue.1
, pp. 53-60
-
-
Wang, X.B.1
Giscombe, R.2
Yan, Z.3
Heiden, T.4
Xu, D.5
Lefvert, A.K.6
-
18
-
-
44349150012
-
Inhibitory B7-family molecules in the tumour microenvironment
-
Jun
-
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008 Jun;8(6):467-77.
-
(2008)
Nat Rev Immunol
, vol.8
, Issue.6
, pp. 467-477
-
-
Zou, W.1
Chen, L.2
-
19
-
-
0028852073
-
Cytotoxic T lymphocyteassociated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail
-
Oct 20
-
Leung HT, Bradshaw J, Cleaveland JS, Linsley PS. Cytotoxic T lymphocyteassociated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. J Biol Chem 1995 Oct 20;270(42):25107-14.
-
(1995)
J Biol Chem
, vol.270
, Issue.42
, pp. 25107-25114
-
-
Leung, H.T.1
Bradshaw, J.2
Cleaveland, J.S.3
Linsley, P.S.4
-
20
-
-
0030176371
-
Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement
-
Jun
-
Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996 Jun;4(6):535-43.
-
(1996)
Immunity
, vol.4
, Issue.6
, pp. 535-543
-
-
Linsley, P.S.1
Bradshaw, J.2
Greene, J.3
Peach, R.4
Bennett, K.L.5
Mittler, R.S.6
-
21
-
-
0034776158
-
Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells
-
Nov
-
Wang XB, Zheng CY, Giscombe R, Lefvert AK. Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells. Scand J Immunol 2001 Nov;54(5):453-8.
-
(2001)
Scand J Immunol
, vol.54
, Issue.5
, pp. 453-458
-
-
Wang, X.B.1
Zheng, C.Y.2
Giscombe, R.3
Lefvert, A.K.4
-
22
-
-
84890933630
-
Update on immune checkpoint inhibitors in lung cancer
-
Jan
-
Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Control 2014 Jan;21(1):80-9.
-
(2014)
Cancer Control
, vol.21
, Issue.1
, pp. 80-89
-
-
Creelan, B.C.1
-
23
-
-
84863783251
-
Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)
-
Aug
-
Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 2012 Aug;77(2):306-11.
-
(2012)
Lung Cancer
, vol.77
, Issue.2
, pp. 306-311
-
-
Erfani, N.1
Mehrabadi, S.M.2
Ghayumi, M.A.3
Haghshenas, M.R.4
Mojtahedi, Z.5
Ghaderi, A.6
-
24
-
-
0031058008
-
Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro
-
Jan
-
Vanky F, Nagy N, Hising C, Sjovall K, Larson B, Klein E. Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol Immunother 1997 Jan;43(6):317-23.
-
(1997)
Cancer Immunol Immunother
, vol.43
, Issue.6
, pp. 317-323
-
-
Vanky, F.1
Nagy, N.2
Hising, C.3
Sjovall, K.4
Larson, B.5
Klein, E.6
-
25
-
-
0029902952
-
TGF-beta 1 overexpression in breast cancer
-
Nov
-
Christeli E, Zoumpourlis V, Kiaris H, Ergazaki M, Vassilaros S, Spandidos D. TGF-beta 1 overexpression in breast cancer. Oncol Rep 1996 Nov;3 (6):1115-8.
-
(1996)
Oncol Rep
, vol.3
, Issue.6
, pp. 1115-1118
-
-
Christeli, E.1
Zoumpourlis, V.2
Kiaris, H.3
Ergazaki, M.4
Vassilaros, S.5
Spandidos, D.6
-
26
-
-
33748987908
-
Cancer despite immunosurveillance: immunoselection and immunosubversion
-
Oct
-
Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006 Oct;6 (10):715-27.
-
(2006)
Nat Rev Immunol
, vol.6
, Issue.10
, pp. 715-727
-
-
Zitvogel, L.1
Tesniere, A.2
Kroemer, G.3
-
27
-
-
0031054242
-
CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics
-
Feb 3
-
van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997 Feb 3;185(3):393-403.
-
(1997)
J Exp Med
, vol.185
, Issue.3
, pp. 393-403
-
-
van der Merwe, P.A.1
Bodian, D.L.2
Daenke, S.3
Linsley, P.4
Davis, S.J.5
-
28
-
-
0035057078
-
B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4
-
Apr
-
Mandelbrot DA, Oosterwegel MA, Shimizu K, Yamada A, Freeman GJ, Mitchell RN, et al. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. J Clin Invest 2001 Apr;107(7):881-7.
-
(2001)
J Clin Invest
, vol.107
, Issue.7
, pp. 881-887
-
-
Mandelbrot, D.A.1
Oosterwegel, M.A.2
Shimizu, K.3
Yamada, A.4
Freeman, G.J.5
Mitchell, R.N.6
-
29
-
-
65349119978
-
CD28 and CTLA-4 coreceptor expression and signal transduction
-
May
-
Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009 May;229(1):12-26.
-
(2009)
Immunol Rev
, vol.229
, Issue.1
, pp. 12-26
-
-
Rudd, C.E.1
Taylor, A.2
Schneider, H.3
-
30
-
-
84866351492
-
Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy
-
Sep
-
Kissick HT, Ireland DJ, Krishnan S, Madondo M, Beilharz MW. Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy. Immunol Cell Biol 2012 Sep;90(8):822-6.
-
(2012)
Immunol Cell Biol
, vol.90
, Issue.8
, pp. 822-826
-
-
Kissick, H.T.1
Ireland, D.J.2
Krishnan, S.3
Madondo, M.4
Beilharz, M.W.5
-
31
-
-
36549027289
-
Anti-CTLA4 antibody clinical trials in melanoma
-
Sep
-
Ribas A. Anti-CTLA4 antibody clinical trials in melanoma. Update Cancer Ther 2007 Sep;2(3):133-9.
-
(2007)
Update Cancer Ther
, vol.2
, Issue.3
, pp. 133-139
-
-
Ribas, A.1
-
32
-
-
84876810947
-
The engagement of CTLA-4 on primary melanoma cell lines induces antibodydependent cellular cytotoxicity and TNF-alpha production
-
Laurent S, Queirolo P, Boero S, Salvi S, Piccioli P, Boccardo S, et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibodydependent cellular cytotoxicity and TNF-alpha production. J Transl Med 2013;11:108.
-
(2013)
J Transl Med
, vol.11
, pp. 108
-
-
Laurent, S.1
Queirolo, P.2
Boero, S.3
Salvi, S.4
Piccioli, P.5
Boccardo, S.6
-
33
-
-
84878936788
-
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells
-
Jul
-
Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013 Jul;1 (1):32-42.
-
(2013)
Cancer Immunol Res
, vol.1
, Issue.1
, pp. 32-42
-
-
Selby, M.J.1
Engelhardt, J.J.2
Quigley, M.3
Henning, K.A.4
Chen, T.5
Srinivasan, M.6
-
34
-
-
0041629528
-
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
-
Jul 15
-
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 Jul 15;21(14):2636-44.
-
(2003)
J Clin Oncol
, vol.21
, Issue.14
, pp. 2636-2644
-
-
Vogelzang, N.J.1
Rusthoven, J.J.2
Symanowski, J.3
Denham, C.4
Kaukel, E.5
Ruffie, P.6
-
36
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Apr
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 Apr;12(4):252-64.
-
(2012)
Nat Rev Cancer
, vol.12
, Issue.4
, pp. 252-264
-
-
Pardoll, D.M.1
-
37
-
-
77957273591
-
Improved endpoints for cancer immunotherapy trials
-
Sep 22
-
Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010 Sep 22;102(18):1388-97.
-
(2010)
J Natl Cancer Inst
, vol.102
, Issue.18
, pp. 1388-1397
-
-
Hoos, A.1
Eggermont, A.M.2
Janetzki, S.3
Hodi, F.S.4
Ibrahim, R.5
Anderson, A.6
-
38
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Aug 19
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 Aug 19;363(8):711-23.
-
(2010)
N Engl J Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
-
39
-
-
84859158384
-
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
-
Apr
-
Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012 Apr;24(2):207-12.
-
(2012)
Curr Opin Immunol
, vol.24
, Issue.2
, pp. 207-212
-
-
Topalian, S.L.1
Drake, C.G.2
Pardoll, D.M.3
-
40
-
-
77953747963
-
The PD-1 pathway in tolerance and autoimmunity
-
Jul
-
Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010 Jul;236:219-42.
-
(2010)
Immunol Rev
, vol.236
, pp. 219-242
-
-
Francisco, L.M.1
Sage, P.T.2
Sharpe, A.H.3
-
41
-
-
33646367200
-
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors
-
Mar
-
Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006 Mar;8(3): 190-8.
-
(2006)
Neoplasia
, vol.8
, Issue.3
, pp. 190-198
-
-
Ghebeh, H.1
Mohammed, S.2
Al-Omair, A.3
Qattan, A.4
Lehe, C.5
Al-Qudaihi, G.6
-
42
-
-
33847611968
-
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
-
Feb 27
-
Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007 Feb 27;104(9):3360-5.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, Issue.9
, pp. 3360-3365
-
-
Hamanishi, J.1
Mandai, M.2
Iwasaki, M.3
Okazaki, T.4
Tanaka, Y.5
Yamaguchi, K.6
-
43
-
-
34247532726
-
Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer
-
Apr 1
-
Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007 Apr 1;13(7):2151-7.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.7
, pp. 2151-2157
-
-
Nomi, T.1
Sho, M.2
Akahori, T.3
Hamada, K.4
Kubo, A.5
Kanehiro, H.6
-
44
-
-
20244384862
-
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
-
Apr 15
-
Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005 Apr 15;11(8):2947-53.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.8
, pp. 2947-2953
-
-
Ohigashi, Y.1
Sho, M.2
Yamada, Y.3
Tsurui, Y.4
Hamada, K.5
Ikeda, N.6
-
45
-
-
34447646310
-
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
-
Jul
-
Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007 Jul;27(1):111-22.
-
(2007)
Immunity
, vol.27
, Issue.1
, pp. 111-122
-
-
Butte, M.J.1
Keir, M.E.2
Phamduy, T.B.3
Sharpe, A.H.4
Freeman, G.J.5
-
46
-
-
84861064002
-
Programmed death ligand 2 in cancer-induced immune suppression
-
Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012;2012 656340.
-
(2012)
Clin Dev Immunol
, vol.2012
, pp. 656340
-
-
Rozali, E.N.1
Hato, S.V.2
Robinson, B.W.3
Lake, R.A.4
Lesterhuis, W.J.5
-
47
-
-
0042170392
-
Differential binding properties of B7-H1 and B7-DC to programmed death-1
-
Aug 1
-
Youngnak P, Kozono Y, Kozono H, Iwai H, Otsuki N, Jin H, et al. Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun 2003 Aug 1;307(3):672-7.
-
(2003)
Biochem Biophys Res Commun
, vol.307
, Issue.3
, pp. 672-677
-
-
Youngnak, P.1
Kozono, Y.2
Kozono, H.3
Iwai, H.4
Otsuki, N.5
Jin, H.6
-
48
-
-
29744462591
-
PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrinmediated adhesion
-
Dec
-
Saunders PA, Hendrycks VR, Lidinsky WA, Woods ML. PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrinmediated adhesion. Eur J Immunol 2005 Dec;35(12):3561-9.
-
(2005)
Eur J Immunol
, vol.35
, Issue.12
, pp. 3561-3569
-
-
Saunders, P.A.1
Hendrycks, V.R.2
Lidinsky, W.A.3
Woods, M.L.4
-
49
-
-
84890888514
-
Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities
-
Jan
-
Merelli B, Massi D, Cattaneo L, Mandala M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014 Jan;89(1):140-65.
-
(2014)
Crit Rev Oncol Hematol
, vol.89
, Issue.1
, pp. 140-165
-
-
Merelli, B.1
Massi, D.2
Cattaneo, L.3
Mandala, M.4
-
50
-
-
32544459770
-
Restoring function in exhausted CD8 T cells during chronic viral infection
-
Feb 9
-
Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006 Feb 9;439(7077):682-7.
-
(2006)
Nature
, vol.439
, Issue.7077
, pp. 682-687
-
-
Barber, D.L.1
Wherry, E.J.2
Masopust, D.3
Zhu, B.4
Allison, J.P.5
Sharpe, A.H.6
-
51
-
-
5844264920
-
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
-
Mar
-
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001 Mar;2(3):261-8.
-
(2001)
Nat Immunol
, vol.2
, Issue.3
, pp. 261-268
-
-
Latchman, Y.1
Wood, C.R.2
Chernova, T.3
Chaudhary, D.4
Borde, M.5
Chernova, I.6
-
52
-
-
18544380239
-
Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
-
Aug
-
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002 Aug;8(8):793-800.
-
(2002)
Nat Med
, vol.8
, Issue.8
, pp. 793-800
-
-
Dong, H.1
Strome, S.E.2
Salomao, D.R.3
Tamura, H.4
Hirano, F.5
Flies, D.B.6
-
53
-
-
33645736792
-
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
-
Apr 1
-
Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006 Apr 1;66(7):3381-5.
-
(2006)
Cancer Res
, vol.66
, Issue.7
, pp. 3381-3385
-
-
Thompson, R.H.1
Kuntz, S.M.2
Leibovich, B.C.3
Dong, H.4
Lohse, C.M.5
Webster, W.S.6
-
54
-
-
33745197352
-
Blockade of PDL1 (B7-H1) augments human tumor-specific T cell responses in vitro
-
Jul 15
-
Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, et al. Blockade of PDL1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006 Jul 15;119(2):317-27.
-
(2006)
Int J Cancer
, vol.119
, Issue.2
, pp. 317-327
-
-
Blank, C.1
Kuball, J.2
Voelkl, S.3
Wiendl, H.4
Becker, B.5
Walter, B.6
-
55
-
-
70349562580
-
Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
-
Aug 20
-
Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009 Aug 20;114 (8):1528-36.
-
(2009)
Blood
, vol.114
, Issue.8
, pp. 1528-1536
-
-
Mumprecht, S.1
Schurch, C.2
Schwaller, J.3
Solenthaler, M.4
Ochsenbein, A.F.5
-
56
-
-
70349561448
-
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
-
Aug 20
-
Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009 Aug 20;114(8):1545-52.
-
(2009)
Blood
, vol.114
, Issue.8
, pp. 1545-1552
-
-
Zhang, L.1
Gajewski, T.F.2
Kline, J.3
-
57
-
-
84925529257
-
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
-
Jan
-
Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2015 Jan;21(1):24-33.
-
(2015)
Trends Mol Med
, vol.21
, Issue.1
, pp. 24-33
-
-
Ohaegbulam, K.C.1
Assal, A.2
Lazar-Molnar, E.3
Yao, Y.4
Zang, X.5
-
58
-
-
73949088551
-
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
-
Dec 21
-
Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009 Dec 21;206(13):3015-29.
-
(2009)
J Exp Med
, vol.206
, Issue.13
, pp. 3015-3029
-
-
Francisco, L.M.1
Salinas, V.H.2
Brown, K.E.3
Vanguri, V.K.4
Freeman, G.J.5
Kuchroo, V.K.6
-
59
-
-
45549098562
-
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR
-
Jun 3
-
Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008 Jun 3;105(22):7797-802.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.22
, pp. 7797-7802
-
-
Sauer, S.1
Bruno, L.2
Hertweck, A.3
Finlay, D.4
Leleu, M.5
Spivakov, M.6
-
60
-
-
84923078390
-
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
-
Nov 27
-
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014 Nov 27;515(7528):558-62.
-
(2014)
Nature
, vol.515
, Issue.7528
, pp. 558-562
-
-
Powles, T.1
Eder, J.P.2
Fine, G.D.3
Braiteh, F.S.4
Loriot, Y.5
Cruz, C.6
-
61
-
-
36048963838
-
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems
-
Nov
-
Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De MA, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007 Nov;117(11):3383-92.
-
(2007)
J Clin Invest
, vol.117
, Issue.11
, pp. 3383-3392
-
-
Grosso, J.F.1
Kelleher, C.C.2
Harris, T.J.3
Maris, C.H.4
Hipkiss, E.L.5
De, M.A.6
-
62
-
-
77957744369
-
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
-
Sep 27
-
Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010 Sep 27;207(10):2187-94.
-
(2010)
J Exp Med
, vol.207
, Issue.10
, pp. 2187-2194
-
-
Sakuishi, K.1
Apetoh, L.2
Sullivan, J.M.3
Blazar, B.R.4
Kuchroo, V.K.5
Anderson, A.C.6
-
63
-
-
77957723967
-
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8+ T cell dysfunction in melanoma patients
-
Sep 27
-
Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010 Sep 27;207(10):2175-86.
-
(2010)
J Exp Med
, vol.207
, Issue.10
, pp. 2175-2186
-
-
Fourcade, J.1
Sun, Z.2
Benallaoua, M.3
Guillaume, P.4
Luescher, I.F.5
Sander, C.6
-
64
-
-
67650966949
-
Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma
-
Aug
-
Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC, et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2009 Aug;137(2):682-90.
-
(2009)
Gastroenterology
, vol.137
, Issue.2
, pp. 682-690
-
-
Gehring, A.J.1
Ho, Z.Z.2
Tan, A.T.3
Aung, M.O.4
Lee, K.H.5
Tan, K.C.6
-
65
-
-
54449088740
-
Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade
-
Sep 30
-
Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A 2008 Sep 30;105(39):15016-21.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.39
, pp. 15016-15021
-
-
Blackburn, S.D.1
Shin, H.2
Freeman, G.J.3
Wherry, E.J.4
-
66
-
-
66949111877
-
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients
-
May 1
-
Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009 May 1;182(9):5240-9.
-
(2009)
J Immunol
, vol.182
, Issue.9
, pp. 5240-5249
-
-
Fourcade, J.1
Kudela, P.2
Sun, Z.3
Shen, H.4
Land, S.R.5
Lenzner, D.6
-
67
-
-
79955530122
-
MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis
-
May 1
-
Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2011 May 1;186(9):5173-83.
-
(2011)
J Immunol
, vol.186
, Issue.9
, pp. 5173-5183
-
-
Hemon, P.1
Jean-Louis, F.2
Ramgolam, K.3
Brignone, C.4
Viguier, M.5
Bachelez, H.6
-
68
-
-
0030902983
-
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein
-
May 27
-
Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A 1997 May 27;94(11):5744-9.
-
(1997)
Proc Natl Acad Sci U S A
, vol.94
, Issue.11
, pp. 5744-5749
-
-
Huard, B.1
Mastrangeli, R.2
Prigent, P.3
Bruniquel, D.4
Donini, S.5
El-Tayar, N.6
-
70
-
-
2142815854
-
Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo
-
May 1
-
Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 2004 May 1;172(9):5450-5.
-
(2004)
J Immunol
, vol.172
, Issue.9
, pp. 5450-5455
-
-
Workman, C.J.1
Cauley, L.S.2
Kim, I.J.3
Blackman, M.A.4
Woodland, D.L.5
Vignali, D.A.6
-
71
-
-
19544374904
-
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells
-
Jun
-
Macon-Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005 Jun;115(2):170-8.
-
(2005)
Immunology
, vol.115
, Issue.2
, pp. 170-178
-
-
Macon-Lemaitre, L.1
Triebel, F.2
-
72
-
-
11844269957
-
Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)
-
Jan 15
-
Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 2005 Jan 15;174 (2):688-95.
-
(2005)
J Immunol
, vol.174
, Issue.2
, pp. 688-695
-
-
Workman, C.J.1
Vignali, D.A.2
-
73
-
-
84879085032
-
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
-
Jun
-
Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, et al. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 2013 Jun;31(3):707-13.
-
(2013)
Invest New Drugs
, vol.31
, Issue.3
, pp. 707-713
-
-
Wang-Gillam, A.1
Plambeck-Suess, S.2
Goedegebuure, P.3
Simon, P.O.4
Mitchem, J.B.5
Hornick, J.R.6
-
74
-
-
70349669259
-
A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma
-
Oct 1
-
Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009 Oct 1;15(19):6225-31.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.19
, pp. 6225-6231
-
-
Brignone, C.1
Escudier, B.2
Grygar, C.3
Marcu, M.4
Triebel, F.5
-
75
-
-
0037203867
-
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
-
Jan 31
-
Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002 Jan 31;415(6871): 536-41.
-
(2002)
Nature
, vol.415
, Issue.6871
, pp. 536-541
-
-
Monney, L.1
Sabatos, C.A.2
Gaglia, J.L.3
Ryu, A.4
Waldner, H.5
Chernova, T.6
-
76
-
-
30044434075
-
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
-
Dec
-
Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005 Dec;6(12):1245-52.
-
(2005)
Nat Immunol
, vol.6
, Issue.12
, pp. 1245-1252
-
-
Zhu, C.1
Anderson, A.C.2
Schubart, A.3
Xiong, H.4
Imitola, J.5
Khoury, S.J.6
-
77
-
-
36248967595
-
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells
-
Nov 16
-
Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007 Nov 16;318(5853):1141-3.
-
(2007)
Science
, vol.318
, Issue.5853
, pp. 1141-1143
-
-
Anderson, A.C.1
Anderson, D.E.2
Bregoli, L.3
Hastings, W.D.4
Kassam, N.5
Lei, C.6
-
78
-
-
79956103042
-
Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors
-
May 15
-
Ngiow SF, von SB, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011 May 15;71(10):3540-51.
-
(2011)
Cancer Res
, vol.71
, Issue.10
, pp. 3540-3551
-
-
Ngiow, S.F.1
von, S.B.2
Akiba, H.3
Yagita, H.4
Teng, M.W.5
Smyth, M.J.6
-
79
-
-
79955977180
-
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
-
Apr 28
-
Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011 Apr 28;117(17):4501-10.
-
(2011)
Blood
, vol.117
, Issue.17
, pp. 4501-4510
-
-
Zhou, Q.1
Munger, M.E.2
Veenstra, R.G.3
Weigel, B.J.4
Hirashima, M.5
Munn, D.H.6
-
80
-
-
59849116262
-
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients
-
Oct
-
Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 2008 Oct;31(8):781-91.
-
(2008)
J Immunother
, vol.31
, Issue.8
, pp. 781-791
-
-
Fourcade, J.1
Kudela, P.2
Andrade Filho, P.A.3
Janjic, B.4
Land, S.R.5
Sander, C.6
-
81
-
-
49649114804
-
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
-
May 15
-
Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008 May 15;14(10):3044-51.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.10
, pp. 3044-3051
-
-
Berger, R.1
Rotem-Yehudar, R.2
Slama, G.3
Landes, S.4
Kneller, A.5
Leiba, M.6
-
82
-
-
77954899030
-
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
-
Jul 1
-
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010 Jul 1;28(19):3167-75.
-
(2010)
J Clin Oncol
, vol.28
, Issue.19
, pp. 3167-3175
-
-
Brahmer, J.R.1
Drake, C.G.2
Wollner, I.3
Powderly, J.D.4
Picus, J.5
Sharfman, W.H.6
-
83
-
-
84936791837
-
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
-
Jul 9
-
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015 Jul 9;373(2):123-35.
-
(2015)
N Engl J Med
, vol.373
, Issue.2
, pp. 123-135
-
-
Brahmer, J.1
Reckamp, K.L.2
Baas, P.3
Crino, L.4
Eberhardt, W.E.5
Poddubskaya, E.6
-
84
-
-
84888352977
-
Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor
-
Infante JR, Powderly JD, Burris HA, Kittaneh M, Houston Grice J, Smother JF, et al. Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. J Clin Oncol 2013;31.
-
(2013)
J Clin Oncol
, pp. 31
-
-
Infante, J.R.1
Powderly, J.D.2
Burris, H.A.3
Kittaneh, M.4
Houston Grice, J.5
Smother, J.F.6
-
85
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Dec 27
-
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 Dec 27;357(26):2666-76.
-
(2007)
N Engl J Med
, vol.357
, Issue.26
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
Dickler, M.4
Cobleigh, M.5
Perez, E.A.6
-
86
-
-
77955487541
-
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
-
Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 2010;8:71.
-
(2010)
J Transl Med
, vol.8
, pp. 71
-
-
Brignone, C.1
Gutierrez, M.2
Mefti, F.3
Brain, E.4
Jarcau, R.5
Cvitkovic, F.6
-
87
-
-
77950283280
-
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
-
Apr 1
-
Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010 Apr 1;116(7):1757-66.
-
(2010)
Cancer
, vol.116
, Issue.7
, pp. 1757-1766
-
-
Hino, R.1
Kabashima, K.2
Kato, Y.3
Yagi, H.4
Nakamura, M.5
Honjo, T.6
-
88
-
-
79955518331
-
Overall survival and PD-L1 expression in metastasized malignant melanoma
-
May 15
-
Gadiot J, Hooijkaas AI, Kaiser AD, van TH, van BH, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011 May 15;117(10):2192-201.
-
(2011)
Cancer
, vol.117
, Issue.10
, pp. 2192-2201
-
-
Gadiot, J.1
Hooijkaas, A.I.2
Kaiser, A.D.3
van, T.H.4
van, B.H.5
Blank, C.6
-
89
-
-
84891534246
-
Programmed death ligand-1 expression in non-small cell lung cancer
-
Jan
-
Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014 Jan;94(1):107-16.
-
(2014)
Lab Invest
, vol.94
, Issue.1
, pp. 107-116
-
-
Velcheti, V.1
Schalper, K.A.2
Carvajal, D.E.3
Anagnostou, V.K.4
Syrigos, K.N.5
Sznol, M.6
-
90
-
-
84873666114
-
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-yearfollow- up study
-
Nov
-
Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-yearfollow- up study. Tumori 2012 Nov;98(6):751-5.
-
(2012)
Tumori
, vol.98
, Issue.6
, pp. 751-755
-
-
Chen, Y.B.1
Mu, C.Y.2
Huang, J.A.3
-
91
-
-
34250177269
-
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
-
Mar 15
-
Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007 Mar 15;13(6):1757-61.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.6
, pp. 1757-1761
-
-
Thompson, R.H.1
Dong, H.2
Lohse, C.M.3
Leibovich, B.C.4
Blute, M.L.5
Cheville, J.C.6
-
92
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Jul 11
-
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013 Jul 11;369(2):122-33.
-
(2013)
N Engl J Med
, vol.369
, Issue.2
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
Postow, M.A.4
Rizvi, N.A.5
Lesokhin, A.M.6
-
93
-
-
84942890493
-
Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies
-
Jul 15
-
Heskamp S, Hobo W, Molkenboer-Kuenen JD, Olive D, Oyen WJ, Dolstra H, et al. Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. Cancer Res 2015 Jul 15;75(14):2928-36.
-
(2015)
Cancer Res
, vol.75
, Issue.14
, pp. 2928-2936
-
-
Heskamp, S.1
Hobo, W.2
Molkenboer-Kuenen, J.D.3
Olive, D.4
Oyen, W.J.5
Dolstra, H.6
-
94
-
-
84864959383
-
New roads open up for implementing immunotherapy in mesothelioma
-
Cornelissen R, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Aerts JG, et al. New roads open up for implementing immunotherapy in mesothelioma. Clin Dev Immunol 2012;2012 927240.
-
(2012)
Clin Dev Immunol
, vol.2012
-
-
Cornelissen, R.1
Heuvers, M.E.2
Maat, A.P.3
Hendriks, R.W.4
Hoogsteden, H.C.5
Aerts, J.G.6
-
95
-
-
84861453989
-
Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies
-
Sep 1
-
Izzi V, Masuelli L, Tresoldi I, Foti C, Modesti A, Bei R. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett 2012 Sep 1;322(1):18-34.
-
(2012)
Cancer Lett
, vol.322
, Issue.1
, pp. 18-34
-
-
Izzi, V.1
Masuelli, L.2
Tresoldi, I.3
Foti, C.4
Modesti, A.5
Bei, R.6
-
96
-
-
77955558708
-
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
-
Oct
-
Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, Ishimine A, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 2010 Oct;59(10):1543-9.
-
(2010)
Cancer Immunol Immunother
, vol.59
, Issue.10
, pp. 1543-1549
-
-
Yamada, N.1
Oizumi, S.2
Kikuchi, E.3
Shinagawa, N.4
Konishi-Sakakibara, J.5
Ishimine, A.6
-
97
-
-
0019994040
-
Lymphocytic infiltration of pleural mesothelioma and its significance for survival
-
Leigh AR, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 1982;61:1007-9.
-
(1982)
S Afr Med J
, vol.61
, pp. 1007-1009
-
-
Leigh, A.R.1
Webster, I.2
-
98
-
-
40949119354
-
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
-
Apr
-
Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L, Keshavjee S, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2008 Apr;135(4):823-9.
-
(2008)
J Thorac Cardiovasc Surg
, vol.135
, Issue.4
, pp. 823-829
-
-
Anraku, M.1
Cunningham, K.S.2
Yun, Z.3
Tsao, M.S.4
Zhang, L.5
Keshavjee, S.6
-
99
-
-
0036704354
-
No relationship between tumour infiltrating lymphocytes and overall survival is seen in malignant mesothelioma of the pleura
-
Aug
-
Mudhar HS, Fisher PM, Wallace WA. No relationship between tumour infiltrating lymphocytes and overall survival is seen in malignant mesothelioma of the pleura. Eur J Surg Oncol 2002 Aug;28(5):564-5.
-
(2002)
Eur J Surg Oncol
, vol.28
, Issue.5
, pp. 564-565
-
-
Mudhar, H.S.1
Fisher, P.M.2
Wallace, W.A.3
-
100
-
-
84876522514
-
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity
-
Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One 2013;8(4):e61895.
-
(2013)
PLoS One
, vol.8
, Issue.4
-
-
Lesterhuis, W.J.1
Salmons, J.2
Nowak, A.K.3
Rozali, E.N.4
Khong, A.5
Dick, I.M.6
-
101
-
-
84864886189
-
CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma
-
Aug
-
Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de PM. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther 2012 Aug;11(8):1809-19.
-
(2012)
Mol Cancer Ther
, vol.11
, Issue.8
, pp. 1809-1819
-
-
Wu, L.1
Yun, Z.2
Tagawa, T.3
Rey-McIntyre, K.4
de, P.M.5
-
102
-
-
84856577906
-
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey
-
Mar
-
Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collova E, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012 Mar;75(3):360-7.
-
(2012)
Lung Cancer
, vol.75
, Issue.3
, pp. 360-367
-
-
Zucali, P.A.1
Simonelli, M.2
Michetti, G.3
Tiseo, M.4
Ceresoli, G.L.5
Collova, E.6
-
103
-
-
84907651087
-
A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients
-
Calabro L, Morra A, Fonsatti E, Cuataia O, Fazio C, Danielli R, et al. A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. J Clin Oncol 2014;32.
-
(2014)
J Clin Oncol
, pp. 32
-
-
Calabro, L.1
Morra, A.2
Fonsatti, E.3
Cuataia, O.4
Fazio, C.5
Danielli, R.6
-
104
-
-
84977745299
-
A randomized, double-blind study comparing tremelimumab to placebo in second and third line treatment of subjects with unresectable pleural or peritoneal mesothelioma
-
Kindler HL, Di Pietro A, Robbins PB, Hong S, Shalabi A, Ibrahim R, et al. A randomized, double-blind study comparing tremelimumab to placebo in second and third line treatment of subjects with unresectable pleural or peritoneal mesothelioma. J Thorac Oncol 2013;8.
-
(2013)
J Thorac Oncol
, pp. 8
-
-
Kindler, H.L.1
Di Pietro, A.2
Robbins, P.B.3
Hong, S.4
Shalabi, A.5
Ibrahim, R.6
-
105
-
-
84907674237
-
Randomized, double-blind, placebo-controlled study of tremelimumab for second and third-line treatment of unresectable pleural or peritoneal mesothelioma
-
Maio M, Scherpereel A, Di Pietro A, Vasey P, Tsao AS, Calabrò L, et al. Randomized, double-blind, placebo-controlled study of tremelimumab for second and third-line treatment of unresectable pleural or peritoneal mesothelioma. J Clin Oncol 2014;32.
-
(2014)
J Clin Oncol
, pp. 32
-
-
Maio, M.1
Scherpereel, A.2
Di Pietro, A.3
Vasey, P.4
Tsao, A.S.5
Calabrò, L.6
-
106
-
-
84902522051
-
B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis
-
Jul
-
MansfieldAS,RodenAC,Peikert T,SheininYM,HarringtonSM,KrcoCJ, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014 Jul;9(7):1036-40.
-
(2014)
J Thorac Oncol
, vol.9
, Issue.7
, pp. 1036-1040
-
-
Mansfield, A.S.1
Roden, A.C.2
Peikert, T.3
Sheinin, Y.M.4
Harrington, S.M.5
Krco, C.J.6
-
107
-
-
84977740936
-
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)
-
Cedres S, Ponce Aix S, Zugazagoitia J, Anguita A, Sansano I, Navarro A, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Ann Oncol 2014;25(5).
-
(2014)
Ann Oncol
, vol.25
, Issue.5
-
-
Cedres, S.1
Ponce Aix, S.2
Zugazagoitia, J.3
Anguita, A.4
Sansano, I.5
Navarro, A.6
-
108
-
-
84925004185
-
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)
-
Cedres S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One 2015;10(3):e0121071.
-
(2015)
PLoS One
, vol.10
, Issue.3
-
-
Cedres, S.1
Ponce-Aix, S.2
Zugazagoitia, J.3
Sansano, I.4
Enguita, A.5
Navarro-Mendivil, A.6
-
109
-
-
85029889678
-
PD-L1 expression in malignant mesothelioma: an immunohistochemical analysis of 33 cases
-
Cowan ML, Forde PM, Taube JM, Illei PB. PD-L1 expression in malignant mesothelioma: an immunohistochemical analysis of 33 cases. Lab Invest 2014;94.
-
(2014)
Lab Invest
, pp. 94
-
-
Cowan, M.L.1
Forde, P.M.2
Taube, J.M.3
Illei, P.B.4
-
110
-
-
84975179144
-
Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028
-
Alley EW, Molife LR, Santoro A, Beckey K, Yuan S, Cheng JD, et al. Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028. In: Proceedings of the 16th annual meeting of the American Association for Cancer Research, 18-22; 2015.
-
(2015)
Proceedings of the 16th annual meeting of the American Association for Cancer Research
, pp. 18-22
-
-
Alley, E.W.1
Molife, L.R.2
Santoro, A.3
Beckey, K.4
Yuan, S.5
Cheng, J.D.6
-
111
-
-
84890814629
-
Breakthrough of the year 2013. Cancer immunotherapy
-
Dec 20
-
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013 Dec 20;342(6165):1432-3.
-
(2013)
Science
, vol.342
, Issue.6165
, pp. 1432-1433
-
-
Couzin-Frankel, J.1
-
112
-
-
85016910370
-
Integrating immune checkpoint blockade with anti-neo/mutated antigens reactivity to increase the clinical outcome of immunotherapy
-
Parmiani Giorgio, Macalli Cristina, Maio Michele. Integrating immune checkpoint blockade with anti-neo/mutated antigens reactivity to increase the clinical outcome of immunotherapy. Vaccines 2015;3(2):420-8.
-
(2015)
Vaccines
, vol.3
, Issue.2
, pp. 420-428
-
-
Giorgio, P.1
Cristina, M.2
Maio, Michele3
-
113
-
-
84882837534
-
Signatures of mutational processes in human cancer
-
Aug 22
-
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013 Aug 22;500(7463):415-21.
-
(2013)
Nature
, vol.500
, Issue.7463
, pp. 415-421
-
-
Alexandrov, L.B.1
Nik-Zainal, S.2
Wedge, D.C.3
Aparicio, S.A.4
Behjati, S.5
Biankin, A.V.6
-
114
-
-
77749279776
-
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
-
Mar 2
-
Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010 Mar 2;107 (9):4275-80.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, Issue.9
, pp. 4275-4280
-
-
Curran, M.A.1
Montalvo, W.2
Yagita, H.3
Allison, J.P.4
-
115
-
-
84929481482
-
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
-
May 21
-
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015 May 21;372(21):2006-17.
-
(2015)
N Engl J Med
, vol.372
, Issue.21
, pp. 2006-2017
-
-
Postow, M.A.1
Chesney, J.2
Pavlick, A.C.3
Robert, C.4
Grossmann, K.5
McDermott, D.6
-
116
-
-
84985921065
-
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results
-
Scott JA, Scott N, Gettinger N, Quan Man Chow L, Juergens RA, Borghaei H, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol 2014;32(5s).
-
(2014)
J Clin Oncol
, vol.32
, Issue.5
-
-
Scott, J.A.1
Scott, N.2
Gettinger, N.3
Quan Man Chow, L.4
Juergens, R.A.5
Borghaei, H.6
-
117
-
-
84863115998
-
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
-
Feb 15
-
Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012 Feb 15;72 (4):917-27.
-
(2012)
Cancer Res
, vol.72
, Issue.4
, pp. 917-927
-
-
Woo, S.R.1
Turnis, M.E.2
Goldberg, M.V.3
Bankoti, J.4
Selby, M.5
Nirschl, C.J.6
-
118
-
-
84856733781
-
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization
-
Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012;7(2):e30852.
-
(2012)
PLoS One
, vol.7
, Issue.2
-
-
Baitsch, L.1
Legat, A.2
Barba, L.3
Fuertes Marraco, S.A.4
Rivals, J.P.5
Baumgaertner, P.6
-
119
-
-
18344375283
-
Immunotherapy and chemotherapy - a practical partnership
-
May
-
Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005 May;5(5):397-405.
-
(2005)
Nat Rev Cancer
, vol.5
, Issue.5
, pp. 397-405
-
-
Lake, R.A.1
Robinson, B.W.2
-
120
-
-
36849035139
-
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies
-
Dec 15
-
O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007 Dec 15;110(12):2614-27.
-
(2007)
Cancer
, vol.110
, Issue.12
, pp. 2614-2627
-
-
O'Day, S.J.1
Hamid, O.2
Urba, W.J.3
-
121
-
-
77953378992
-
CTLA-4 blockade: therapeutic potential in cancer treatments
-
Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 2010;3:15-25.
-
(2010)
Onco Targets Ther
, vol.3
, pp. 15-25
-
-
Tarhini, A.A.1
Iqbal, F.2
-
122
-
-
55949083407
-
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment
-
Nov 10
-
Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008 Nov 10;26(32):5275-83.
-
(2008)
J Clin Oncol
, vol.26
, Issue.32
, pp. 5275-5283
-
-
Fong, L.1
Small, E.J.2
-
123
-
-
34548191221
-
Update on anti-CTLA-4 antibodies in clinical trials
-
Aug
-
Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007 Aug;7(8):1245-56.
-
(2007)
Expert Opin Biol Ther
, vol.7
, Issue.8
, pp. 1245-1256
-
-
Langer, L.F.1
Clay, T.M.2
Morse, M.A.3
-
124
-
-
0032404099
-
Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice
-
Dec 1
-
Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 1998 Dec 1;58(23):5301-4.
-
(1998)
Cancer Res
, vol.58
, Issue.23
, pp. 5301-5304
-
-
Mokyr, M.B.1
Kalinichenko, T.2
Gorelik, L.3
Bluestone, J.A.4
-
125
-
-
84977741391
-
T-cell inflamed phenotype and PDL1 expression in malignant mesothelioma
-
Kindler Hedy Lee, Zuo Zhixiang, Khattri Arun, Keck Michaela K, Vigneswaran Wickii, Husain Aliya Noor, et al. T-cell inflamed phenotype and PDL1 expression in malignant mesothelioma. J Clin Oncol 2014;32(5s).
-
(2014)
J Clin Oncol
, vol.32
, Issue.5
-
-
Lee, K.H.1
Zhixiang, Z.2
Arun, K.3
Keck Michaela, K.4
Wickii, V.5
Noor, H.A.6
|